LABELLING

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING

HDPE bottle

1. Name of the medicinal product

[HA699 trade name][*] Dolutegravir (as sodium)/lamivudine/tenofovir disoproxil fumarate 50 mg/300 mg/300 mg tablets

Dolutegravir (as sodium)/lamivudine/tenofovir disoproxil fumarate

2. Statement of active substance

Each film-coated tablet contains 50 mg dolutegravir (as sodium), 300 mg lamivudine and 300 mg tenofovir disoproxil fumarate

3. List of excipients

Contains mannitol

4. Pharmaceutical form and contents

Film-coated tablets

30 tablets

90 tablets

180 tablets

5. Method and route of administration

Oral use

Read the patient information leaflet before use.

6. Special warning that the medicinal product must be stored out of the reach and sight of children

Keep this medicine out of the sight and reach of children.

7. Other special warning(s), if necessary

8. Expiry date

EXP {MM/YYYY}

9. Special storage conditions

Do not store above 30°C. Protect from moisture

Discard 30 days after first opening. (*30 tablets pack size*)

Discard 90 days after first opening. *(90 tablets pack size)*

Discard 180 days after first opening. *(180 tablets pack size)*

[*] Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate

11. Name and address of the supplier

Sun Pharmaceutical Industries Limited
Sun House, 201 B/1
Western Express Highway
Goregaon (East)
Mumbai 400 063
India

12. WHO Reference Number (Prequalification Programme)

HA699

13. Manufacturer's batch number

<Batch> <Lot> {number}

14. (Advice on) General classification for supply

Medicinal product subject to medical prescription.

15. Instructions on use